High Asymptomatic Carriage With the Omicron Variant in South Africa

Nigel Garrett, Asa Tapley, Jessica Andriesen, Ishen Seocharan, Leigh H. Fisher, Lisa Bunts, Nicole Espy, Carole L. Wallis, April K. Randhawa, Maurine D. Miner, Nzeera Ketter, Margaret Yacovone, Ameena Goga, Yunda Huang, John Hural, Philip Kotze, Linda‐Gail Bekker, Glenda Gray, Lawrence Corey, Khatija Ahmed, Sharlaa Badal‐Faesen, Shaun Barnabas, William Brumskine, Kim Comline, Andreas Diacon, Thozama Dubula, Katherine Gill, Coert Grobbelaar, Craig Innes, Sheetal Kassim, Sheena Kotze, Erica Lazarus, Johannes Lombaard, Angelique Kany Kany Luabeya, Rebone Maboa, Scott Mahoney, Disebo Mahkaza, Moelo Malahleha, Daniel R Malan, Kathryn Mngadi, Nivashnee Naicker, Vimla Naicker, Logashvari Naidoo, Maphoshane Nchabeleng, Mohammed Rassool, Elizabeth Spooner, Hugo Tempelman, Nyaradzo Mgodi, Sufia Dadabhai, Joe Makhema, Harriet Nuwagaba‐Biribonwoha, Taraz Samandari, Peter Elyanu, Roma Chilengi, Zvavahera M. Chirenje, M. Juliana McElrath, Myron S. Cohen, James G. Kublin, Peter B. Gilbert, Melissa Peda, Erica Andersen‐Nissen, Guido Ferrari, Manuel Villarán, Azwidihwi Takalani, Marianne Gildea, Michelle Nebergall, Carrie Sopher, Lori Proulx-Burns, D Govender, Lisa J. Sanders, Jen Hanke, Kagisho Baepanye, Bert Le Roux, Haven Wilvich, Smitha Sripathy, Daciana Margineantu, Valerie Brown, Kim Linton, Haley Howell, Bianca Noronha, Sarah Nikles, Alicia Y. Toledano, Jeanine May, Jill El-Khorazaty, Keshani Naidoo, Kentse Khuto, Fatima Mayat, Lara Fairall, Ian SanneClinical 2022 · DOI

TL;DR

This study reveals a striking 23% asymptomatic carriage rate of the Omicron variant of SARS-CoV-2 in South Africa, a rate significantly higher than observed with previous variants. It also highlights that individuals with lower CD4+ T-cell counts, particularly those with HIV, have a higher likelihood of being infected, underscoring the vulnerability of immunocompromised populations.

What Problem Does This Paper Address?

The emergence of new SARS-CoV-2 variants, like Omicron, poses a constant challenge to public health efforts. Understanding how these variants spread, especially asymptomatically, is crucial for effective control strategies. Prior to Omicron, studies indicated that asymptomatic carriage of SARS-CoV-2 was relatively low, typically under 2%. However, the rapid global spread of Omicron suggested a potential shift in transmission dynamics. This paper addresses the critical question of how prevalent asymptomatic Omicron infection is, particularly in a population with a high burden of HIV, which is known to be associated with more severe COVID-19 outcomes. The authors aim to quantify this asymptomatic carriage rate and explore potential correlations with host factors like CD4+ T-cell counts.

Methods

The study enrolled participants into the Ubuntu multicenter Phase 3 clinical trial in South Africa, designed to assess COVID-19 mRNA vaccine efficacy in individuals with HIV or other comorbidities. A key aspect of the enrollment process involved baseline testing for SARS-CoV-2. This included:

  • Nasopharyngeal Swab for RT-PCR: This is a standard method for detecting active SARS-CoV-2 infection. The Abbott Real-Time SARS-CoV-2 assay was used.
  • SARS-CoV-2 Antibody Status: The Assure Ecotest IgG/IgM Rapid Test was employed to determine if participants had prior exposure to the virus.
  • HIV-Specific Testing: For participants with HIV, CD4+ T-cell counts and HIV viral load were measured.

Crucially, participants were required to be clinically well and asymptomatic at the time of enrollment to receive the vaccine. This design allowed for the identification of individuals who were infected but not exhibiting symptoms. The study also compared its findings to data from previous trials (Sisonke and Ensemble 1) conducted before the Omicron wave.

Datasets

The primary dataset for this study comes from participants enrolled in the Ubuntu clinical trial in South Africa. This trial collected baseline data on SARS-CoV-2 infection status (via RT-PCR and antibody testing) and HIV status (CD4+ T-cell count and viral load) from individuals who were asymptomatic at the time of enrollment. The study also references and compares data from two previous South African trials:

  • Sisonke Study: This trial focused on the Ad26.COV2.S vaccine and was conducted between June and August 2021, during the Beta variant outbreak.
  • Ensemble 1 Trial: This trial also involved the Ad26.COV2.S vaccine and included a subgroup of people with HIV.

These previous datasets provide a baseline for asymptomatic carriage rates with earlier SARS-CoV-2 variants.

Key Insights and Ideas

  • Omicron's Stealthy Spread: The most significant insight is the remarkably high rate of asymptomatic carriage (23%) observed with the Omicron variant. This is a substantial increase compared to pre-Omicron variants, suggesting Omicron's enhanced ability to spread undetected.
  • HIV and Vulnerability: The study reinforces that individuals with HIV, particularly those with lower CD4+ T-cell counts (<500 cells/mm³), are at a higher risk of SARS-CoV-2 infection. This finding is critical for understanding disease burden and prioritizing interventions for immunocompromised populations.
  • Implications for Public Health: The high asymptomatic transmission rate of Omicron poses a major challenge to traditional infection control measures like symptom-triggered testing and contact tracing. It underscores the need for broader testing strategies and potentially enhanced vaccine approaches that aim to prevent infection, not just severe disease.
  • CD4 Count as a Predictor: The strong correlation between lower CD4+ T-cell counts and increased odds of SARS-CoV-2 positivity is a key finding. This suggests that CD4 count could serve as a valuable indicator for identifying individuals at higher risk of infection and potentially prolonged shedding.

Key Results

  • Asymptomatic Carriage Rate: A substantial 23% of participants enrolled in the Ubuntu trial were found to have asymptomatic SARS-CoV-2 infection via RT-PCR. This is approximately a 15-fold increase compared to asymptomatic carriage rates observed in trials conducted before the Omicron variant emerged.
  • HIV and CD4 Count:
    • 33% of people with HIV (PWH) with CD4+ T-cell counts <500 cells/mm³ tested positive for SARS-CoV-2, compared to 19% of PWH with counts ≥500 cells/mm³.
  • A 10-fold decrease in CD4 count was associated with a 3.2-fold higher odds of a positive PCR test, even after adjusting for serostatus.
  • S Gene Dropout: Of the samples tested for specific gene markers, 48% had an RT-PCR cycle threshold (Ct) value <25, and 18% had Ct values ≤20, indicating high viral loads in many asymptomatic carriers. All tested samples showed S gene dropout, a characteristic of Omicron.
  • Previous Variant Carriage: In contrast, studies of previous variants (Beta) showed asymptomatic carriage rates of around 2.4% in similar settings.

Limitations and Future Work

  • Generalizability: The authors acknowledge that the generalizability of their findings might be limited to populations outside of South Africa, particularly those with lower SARS-CoV-2 seroprevalence.
  • Serology Interpretation: Interpreting positive SARS-CoV-2 serology was challenging, as it couldn't definitively distinguish which variant caused the infection or when the infection occurred, potentially including ongoing infections.
  • Future Directions: The study highlights the urgent need for:
  • Second-generation vaccines that aim to prevent infection, not just disease.
  • Enhanced surveillance with rapid testing and real-time genomic sequencing.
  • Larger studies to better understand how immunocompromise influences infection acquisition and clearance.
  • Research into viral persistence and variation among PWH, as persistent shedding could impact transmission and viral evolution, even in those on ART.

Summary updated

Abstract

We report a 23% asymptomatic severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) Omicron carriage rate in participants being enrolled into a clinical trial in South Africa, 15-fold higher than in trials before Omicron. We also found lower CD4 + T-cell counts in persons with human immunodeficiency virus (HIV) strongly correlated with increased odds of being SARS-CoV-2 polymerase chain reaction (PCR) positive.
BibTeX
@inproceedings{garrett2022high,
  author = {Nigel Garrett and Asa Tapley and Jessica Andriesen and Ishen Seocharan and Leigh H. Fisher and Lisa Bunts and Nicole Espy and Carole L. Wallis and April K. Randhawa and Maurine D. Miner and Nzeera Ketter and Margaret Yacovone and Ameena Goga and Yunda Huang and John Hural and Philip Kotze and Linda‐Gail Bekker and Glenda Gray and Lawrence Corey and Khatija Ahmed and Sharlaa Badal‐Faesen and Shaun Barnabas and William Brumskine and Kim Comline and Andreas Diacon and Thozama Dubula and Katherine Gill and Coert Grobbelaar and Craig Innes and Sheetal Kassim and Sheena Kotze and Erica Lazarus and Johannes Lombaard and Angelique Kany Kany Luabeya and Rebone Maboa and Scott Mahoney and Disebo Mahkaza and Moelo Malahleha and Daniel R Malan and Kathryn Mngadi and Nivashnee Naicker and Vimla Naicker and Logashvari Naidoo and Maphoshane Nchabeleng and Mohammed Rassool and Elizabeth Spooner and Hugo Tempelman and Nyaradzo Mgodi and Sufia Dadabhai and Joe Makhema and Harriet Nuwagaba‐Biribonwoha and Taraz Samandari and Peter Elyanu and Roma Chilengi and Zvavahera M. Chirenje and M. Juliana McElrath and Myron S. Cohen and James G. Kublin and Peter B. Gilbert and Melissa Peda and Erica Andersen‐Nissen and Guido Ferrari and Manuel Villarán and Azwidihwi Takalani and Marianne Gildea and Michelle Nebergall and Carrie Sopher and Lori Proulx-Burns and D Govender and Lisa J. Sanders and Jen Hanke and Kagisho Baepanye and Bert Le Roux and Haven Wilvich and Smitha Sripathy and Daciana Margineantu and Valerie Brown and Kim Linton and Haley Howell and Bianca Noronha and Sarah Nikles and Alicia Y. Toledano and Jeanine May and Jill El-Khorazaty and Keshani Naidoo and Azwidihwi Takalani and Kentse Khuto and Fatima Mayat and Lara Fairall and Ian Sanne and Ian Sanne},
  title = {{High Asymptomatic Carriage With the Omicron Variant in South Africa}},
  booktitle = {Clinical},
  year = {2022},
  doi = {10.1093/cid/ciac237},
}
Figure